This study examined the prevalence of primary human immunodeficiency type 1 (HIV-1) drug resistance among recently infected youth in the United States. Of the 55 subjects studied, major mutations conferring HIV drug resistance were present in 10 (18%). Eight (15%) had nonnucleoside reverse-transcriptase inhibitor (NNRTI) mutations, with the majority (6) having the K103N mutation; 2 (4%) had nucleoside reverse-transcriptase inhibitor (NRTI) mutations; and 2 (4%) had protease inhibitor (PI) mutations. Phenotypic drug resistance was present in 12 (22%) subjects: 10 (18%) for NNRTIs, 2 (4%) for NRTIs, and 3 (5.5%) for PIs. The prevalence of primary HIV-1 drug resistance, particularly to NNRTIs, in this group of recently infected youth was high.
An increase in the prevalence of primary HIV-1 genotypic resistance among recently infected individuals, from 8% to 22.7%, was documented in North America between 1995 and 2000 [3] . This study used convenience samples predominately composed of high risk men who have sex with men. The presence of baseline resistance markers, not available on initiation of therapy, was predictive of poorer response to subsequent antiretroviral therapy [3] . However, resistance testing was unavailable on therapy initiation. Studies of the prevalence of HIV-1 drug-resistance markers conducted in Europe have documented similar phenomena, although to a lesser degree [4, 5] . These studies have been conducted predominantly with middleaged white males, and data on the prevalence of HIV-1 drug resistance in recently infected youth are lacking.
Herein are reported the results of Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) study 022, substudy 029, a multicenter study that enrolled recently HIV-1-infected youth who were identified by means of a serologic "detuned" assay, the Organon Technika Dilutional Vironostika sensitive/less sensitive (DV S/LS) test [6] . We present the prevalence of primary genotypic as well as phenotypic HIV-1 drugresistance patterns among these youth.
Subjects, materials, and methods. Antiretroviral naive HIV-1-seropositive youth who were 12-24 years old, were referred to any of the 15 sites (table 1) of the ATN, and were identified as having been recently infected were eligible to participate in ATN 029. Study participants signed an informed consent form that had been approved by the local human subject protection board, and the human experimentation guidelines of the US Department of Health and Human Services were followed.
Recent HIV-1 infection was ascertained by means of a se- rologic detuned assay, the DV S/LS test (bioMérieux) that identifies HIV infection within 180 days of exposure [6] . Briefly, serum samples from all HIV-1-infected subjects, as determined by a positive HIV-1 EIA and Western blot result at individual ATN clinical sites, were tested at the University of Maryland by the DV S/LS test. For the DV S/LS EIA testing, each sample was first tested by DV in the S mode to ensure reactivity, followed by DV testing in the LS mode. Samples giving a reactive result in the S mode but a nonreactive result in the LS mode were considered to represent recent HIV-1 infection [6] . Information on demographics and risk factors for HIV-1 acquisition were recorded. CD4 + T cell count and plasma HIV-1 RNA viral load (VL) were determined at study entry. Plasma was stored centrally at Ϫ70ЊC for batched phenotypic and genotypic analysis of resistance to standard antiretroviral drugs.
Population-based nucleotide-sequence analysis of the HIV-1 protease and reverse-transcriptase gene sequences (55 specimens [GenBank accession numbers DQ832114-DQ832168]) was done centrally, by use of the GeneSeq HIV Assay Protocol (Monogram Biosciences). Final interpretation of the sequence variation data provided by Monogram was done using the International AIDS Society-USA Drug Resistance Mutations interpretation guidelines [7] . Multidrug resistance was defined by the identification of major mutations conferring resistance to drugs in 3 classes.
Phenotypic analysis was performed with a rapid recombinant virus assay (PhenoSense HIV; Monogram Biosciences), which uses test vectors derived from the amplified products of HIV-1 protease and reverse-transcriptase gene sequences from patient viral isolates [8] . Individual drug susceptibility was measured by determining the ratio of the drug concentration required to inhibit 50% (IC 50 ) of the patient's virus to the IC 50 of the drug-sensitive reference virus (IC 50 fold change). An IC 50 fold change for a subject's virus that was higher than that for the drug-sensitive reference virus by more than the drug-specific reduced-susceptibility factor indicated decreased susceptibility to that drug. The reduced-susceptibility factors for the relevant medications were either clinical (C)-or biological assay (BA)-defined fold-change cutoffs and were as follows: abacavir Results. Eighty-eight subjects were identified as having been recently infected with HIV-1 by the detuned assay. Sixteen subjects had no samples collected for drug-resistance testing. Fifteen subjects (17%) had an HIV-1 RNA VL !400 copies/ mL; therefore, drug-resistance testing was not performed. Two additional samples could not be analyzed for drug resistance. Fifty-five subjects from 15 different cities had HIV-1 genotypic and phenotypic testing performed. Nineteen (35%) were female, 36 (65%) were male, and both sexes had a diverse ethnic distribution (table 1). The age was years mean ‫ע‬ SD 19.7 ‫ע‬ 1.9 for males and years for females ( ). The fol-18.6 ‫ע‬ 1.9 P p .06 lowing nonexclusive risk factors for HIV-1 acquisition were present in male subjects: sex with multiple partners (78%), men who have sex with men (81%), recent sexually transmitted diseases (31%), having sex under the influence of drugs or alcohol (36%), exchanging sex for money or drugs (14%), having been a victim of sexual assault (8%), and having an HIVinfected partner (47%). Risk factors for HIV-1 acquisition in female subjects were sex with multiple partners (63%), recent sexually transmitted diseases (53%), having sex under the influence of drugs or alcohol (21%), exchanging sex for money or drugs (5%), having been a victim of sexual assault (16%), Evidence of phenotypic and/or genotypic resistance was identified in 13 subjects (24%): 9 (16%) had genotypic and phenotypic resistance, 1 had genotypic resistance alone, and 3 had phenotypic resistance alone. Major mutations conferring drug resistance were present in 10 subjects (18%) (figure 1). Eight (15%) had nonnucleoside reverse-transcriptase inhibitor (NNRTI) mutations: K103N alone (5), K103N and Y181C (1), Y181C alone (1), and V108I alone (1) . Two (4%) had nucleoside reverse-transcriptase inhibitor (NRTI) mutations: M41L, L74V, and T215F (1); and M184V (1). Two (4%) had protease inhibitor (PI) mutations: L90M (1); and M36I and M46L (1). Evidence of phenotypic drug resistance was present in 12 subjects (22%) (figure 1): 10 (18%) for NNRTI; 2 (4%) for NRTI; and 3 (5.5%) for PI. Two subjects had NNRTI phenotypic resistance alone, and 1 had PI phenotypic resistance alone. One subject had phenotypic and genotypic resistance to NNRTIs and only phenotypic resistance to PIs. One (2%) subject had genotypic and phenotypic resistance to antiretrovirals in all 3 classes (table 2) .
Discussion. The rates of NNRTI-resistant HIV-1 that we report in these recently infected adolescents and young adults are among the highest ever reported in the United States, and the overall rates of drug resistance are concerning. Given the correlation between convenient regimens that lead to improved adherence and superior virologic control, particularly among this age group, simplified regimens are now highly sought after by many clinicians. These data raise public health concerns over the use of NNRTI-based regimens as empiric first-line therapy in HIV-1-infected adolescents without initial screening for resistance.
It is estimated that, of the 40,000 new HIV infections in the United States each year, 25% occur in adolescents 13-19 years of age, and ∼50% of all new infections occur in persons !24 years of age [9] . The mean age among the subjects in this study was 19 years, compared with 35 years and 37 years in other studies characterizing the prevalence of HIV-1 drug resistance among recently infected adults [3, 5, 10] . Most of these studies have been conducted among middle-aged white men, whose risk factor for HIV-1 acquisition was having sex with men [3, 5, 10] . In contrast, the present study is more representative of the sex demographics and risk factors for HIV-1 acquisition among the recently infected youth in the United States [11] . Women composed 35% of this population, 47% of the subjects were African Americans, and 24% were Hispanics. In contrast, the demographic characteristics of other reported US studies have reflected populations whose constituents included as few as 10% females, 16% African Americans, and 10% Hispanics [3, 10] .
The mean CD4 + T cell count and HIV-1 RNA VL of the subjects in this study were similar to those in previous reports [3] [4] [5] 10] . Interestingly, 17% of our subjects had an undetectable VL. A similar observation was reported recently in a French study, in which 26% of patients followed for the first 5 years from the estimated time of seroconversion had at least 1 undetectable HIV-1 RNA VL and 8% had 2 or more undetectable VL measurements in the absence of antiretroviral therapy [12] .
We found a very high prevalence of primary HIV-1 drug resistance among recently infected youth, with 24% having drug-resistance markers overall. The prevalence of phenotypic and genotypic drug resistance to NNRTIs (18% and 15%, respectively) is the highest reported to date and is the predominant factor contributing to the high overall resistance prevalence. Grant et al. documented an increase in NNRTI phenotypic and genotypic drug resistance, from 4% and 6% to 9% and 13%, respectively, between 1999 and 2001 among predominately middle-aged men who have sex with men [10] . Previous studies conducted in North America between 1999 and 2001 have documented a higher prevalence of NRTI phenotypic and genotypic resistance, of 6% and 20%, respectively [3, 10] . In contrast, we observed a lower prevalence of NRTI phenotypic and genotypic resistance, of only 3.6% overall. Similarly, we observed a lower prevalence of phenotypic and genotypic PI resistance and a lower prevalence of triple class resistance than previously reported [3, 10] . This may be explained by the chronology of the studies compared, reflecting a high proportion of NRTI-, PI-, and multidrug-resistant virus transmission between 1999 and 2001, when the transmitted virus pools may have been composed of viruses previously exposed to sequential suboptimal regimens. The present study, conducted during 2004, reflects the increased use of efavirenz-based regimens as the preferred initial antiretroviral regimen recommended by the International AIDS Society-USA Panel. Because of the low genetic barrier for resistance to efavirenz, suboptimal adherence can lead to a single mutation (K103N) conferring high-level resistance to all NNRTIs. Isolated K103N mutations tend not to have impaired replication capacity, which may in part explain the persistence of NNRTI resistance for prolonged periods of time, thus increasing the likelihood of transmission of NNRTIresistant viral strains [13] . This is particularly important in light of the recent increase in high-risk sexual behavior among HIV-1-infected individuals in urban settings [14] .
A limitation of our study is the small size and the convenience sample based on subject referrals to specialized adolescent HIV clinics in 15 centers across the United States. However, there are no other published studies addressing HIV-1 drug resistance in recently infected youth.
The high prevalence of NNRTI genotypic and phenotypic drug resistance in recently infected youth places them at risk of poor response to future NNRTI-based regimens. These observations support the current guidelines for resistance testing in adults and adolescents recently infected with HIV-1 before initiating antiretroviral therapy [15] . Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) sites and support. The present study was scientifically reviewed by the ATN Therapeutic Leadership Group. Network scientific and logistical support was provided by the ATN Coordinating Center at the University of Alabama at Birmingham. Network operations and analytic support was provided by the ATN Data and Operations Center at Westat (Jim Korelitz and Barbara Driver).
